578 results on '"Wahl, Denis"'
Search Results
2. An update on laboratory detection and interpretation of antiphospholipid antibodies for diagnosis of antiphospholipid syndrome: guidance from the ISTH-SSC Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibodies
3. Epidemiology, natural history, diagnosis, and management of ovarian vein thrombosis: a scoping review
4. French protocol for the diagnosis and management of systemic lupus erythematosus
5. Toward harmonized interpretation of anticardiolipin and anti–β2-glycoprotein I antibody detection for diagnosis of antiphospholipid syndrome using defined level intervals and likelihood ratios: communication from the ISTH SSC Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibodies
6. Thrombosis recurrence and major bleeding in non-anticoagulated thrombotic antiphospholipid syndrome patients: Prospective study from antiphospholipid syndrome alliance for clinical trials and international networking (APS ACTION) clinical database and repository (“Registry”)
7. A thrombin-driven neural net diagnoses the antiphospholipid syndrome without the need for interruption of anticoagulation
8. Added value of antiphosphatidylserine/prothrombin antibodies in the workup of obstetric antiphospholipid syndrome: communication from the ISTH SSC Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibodies
9. Effect of weight-adjusted intermediate-dose versus fixed-dose prophylactic anticoagulation with low-molecular-weight heparin on venous thromboembolism among noncritically and critically ill patients with COVID-19: the COVI-DOSE trial, a multicenter, randomised, open-label, phase 4 trial
10. Associations Among Antiphospholipid Antibody Types, Isotypes, and Titers: An AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Study
11. Precipitating factors of catastrophic antiphospholipid syndrome: the role of anticoagulant treatment in a series of 112 patients
12. Frequency and predictors for chronic thromboembolic pulmonary hypertension after a first unprovoked pulmonary embolism: Results from PADIS studies
13. Increased risk of acute and chronic microvascular renal lesions associated with antiphospholipid antibodies in patients with systemic lupus erythematosus: A systematic review and meta-analysis
14. Added value of antiphosphatidylserine/prothrombin antibodies in the workup of thrombotic antiphospholipid syndrome: Communication from the ISTH SSC Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibodies
15. Semiquantitative interpretation of anticardiolipin and antiβ2glycoprotein I antibodies measured with various analytical platforms: Communication from the ISTH SSC Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibodies
16. Antiphospholipid antibodies and the risk of autoimmune hemolytic anemia in patients with systemic lupus erythematosus: A systematic review and meta-analysis
17. Deciphered coagulation profile to diagnose the antiphospholipid syndrome using artificial intelligence
18. Shedding Light on Hemostasis in Patients With Inflammatory Bowel Diseases
19. Cardiovascular manifestations of intermediate and major hyperhomocysteinemia due to vitamin B12 and folate deficiency and/or inherited disorders of one-carbon metabolism: a 3.5-year retrospective cross-sectional study of consecutive patients
20. Direct oral anticoagulants in antiphospholipid syndrome: Meta-analysis of randomized controlled trials
21. The (non‐)sense of detecting anti‐cardiolipin and anti‐β2glycoprotein I IgM antibodies in the antiphospholipid syndrome
22. Antiphospholipid antibodies and the risk of thrombocytopenia in patients with systemic lupus erythematosus: A systematic review and meta-analysis
23. LBP2 Development and validation of a patient-centered autoevaluation questionnaire in systemic lupus erythematosus: LUPIN
24. Viewpoint: Provoked thrombosis in antiphospholipid syndrome
25. Cardiovascular and connective tissue disorder features in FLNA-related PVNH patients: progress towards a refined delineation of this syndrome
26. CT angiography and MRI of hand vascular lesions: technical considerations and spectrum of imaging findings
27. Development of a New International Antiphospholipid Syndrome Classification Criteria Phase I/II Report: Generation and Reduction of Candidate Criteria
28. Increased risk of thrombosis in antiphospholipid syndrome patients treated with direct oral anticoagulants. Results from an international patient-level data meta-analysis
29. Systematic Review of Antiphospholipid Antibodies in COVID-19 Patients: Culprits or Bystanders?
30. Prothrombin conversion is accelerated in the antiphospholipid syndrome and insensitive to thrombomodulin
31. Tocilizumab and refractory Takayasu disease: Four case reports and systematic review
32. Clinical and Prognostic Significance of Non-criteria Antiphospholipid Antibody Tests
33. Disease and Risk Measurement Criteria in Antiphospholipid Syndrome
34. Definition and Epidemiology of Antiphospholipid Syndrome
35. Heart and systemic sclerosis—findings from a national cohort study
36. Antiphospholipid antibodies can identify lupus patients at risk of pulmonary hypertension: A systematic review and meta-analysis
37. New Insights into the Use of Direct Oral Anticoagulants in Non-high Risk Thrombotic APS Patients: Literature Review and Subgroup Analysis from a Meta-analysis
38. Health-Related Quality of Life in Antiphospholipid Syndrome: Current Knowledge and Future Perspectives
39. Health-related quality of life, remission and low lupus disease activity state in patients with systemic lupus erythematosus.
40. 2023 ACR/EULAR antiphospholipid syndrome classification criteria
41. Damage measured by Damage Index for Antiphospholipid Syndrome (DIAPS) in antiphospholipid antibody-positive patients included in the APS ACTION registry.
42. The relevance of “non-criteria” clinical manifestations of antiphospholipid syndrome: 14th International Congress on Antiphospholipid Antibodies Technical Task Force Report on Antiphospholipid Syndrome Clinical Features
43. Patient-level analysis of five international cohorts further confirms the efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies
44. Facteurs et modèles pronostiques de récidive de MTEV
45. Thrombosis Recurrence and Major Bleeding in Non-Anticoagulated Thrombotic Antiphospholipid Syndrome Patients: Prospective Study from Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (Aps Action) Clinical Database and Repository (“Registry”)
46. Risk of venous and arterial thrombosis according to type of antiphospholipid antibodies in adults without systemic lupus erythematosus: A systematic review and meta-analysis
47. Characteristics, prognosis, and outcomes of cutaneous ischemia and gangrene in systemic necrotizing vasculitides: A retrospective multicenter study
48. Efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies: An international and collaborative meta-analysis
49. Le syndrome des antiphospholipides en néphrologie. Atteinte rénale et aspects pratiques de la prise en charge
50. Brief Report on the 11th Meeting of the European Forum on Antiphospholipid Antibodies
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.